Effect of Everolimus Introduction on Cardiac Allograft Vasculopathy—Results of a Randomized, Multicenter Trial

Arora, Satish; Ueland, Thor; Wennerblom, Bertil; Sigurdadottir, Vilborg; Eiskjær, Hans; Bøtker, Hans Erik; Ekmehag, Björn; Jansson, Kjell; Mortensen, Stefan P.; Saunamäki, Kari; Simonsen, Svein; Gude, Einar; Bendz, Bjørn; Solbu, D.; Aukrust, Pål; Gullestad, Lars

doi:10.1097/tp.0b013e31822057f1

Cited by 74 publications

(63 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For these reasons, many trials use IVUS as the gold standard to assess the effect of drug treatments on CAV. 24,25 Despite this, the added value over angiography alone for routine clinical use remains uncertain. 26 In children, there are technical limitations, and it remains an invasive technique usually requiring sedation or anesthesia.…”

Section: Discussionmentioning

confidence: 99%

Detection and Grading of Coronary Allograft Vasculopathy in Children With Contrast-Enhanced Magnetic Resonance Imaging of the Coronary Vessel Wall

Hussain

Fenton

Peel

et al. 2013

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

Background-Coronary allograft vasculopathy is the leading cause of late death after heart transplantation in children. It is poorly detected by conventional angiography. Intravascular ultrasound is invasive and costly. This study shows that magnetic resonance imaging (MRI) late gadolinium enhancement (LGE) of the coronary vessel wall can detect and grade coronary allograft vasculopathy. Methods and Results-Twenty-four children (10 male; age range, 9-17 years) underwent coronary angiography, intravascular ultrasound, and MRI.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection and Grading of Coronary Allograft Vasculopathy in Children With Contrast-Enhanced Magnetic Resonance Imaging of the Coronary Vessel Wall

Hussain

Fenton

Peel

et al. 2013

Circ: Cardiovascular Imaging

View full text Add to dashboard Cite

show abstract

“…A number of studies showed a significant antiproliferation potential of this medication regarding CAV mitigation and deceleration and hence improved long-term mortality after HTx (ref. [20][21][22][23][24] ). Statins represent another medication which can positively influence CAV.…”

Section: Discussionmentioning

confidence: 99%

Monitoring of allograft vasculopathy by intravascular ultrasound one month and one year after heart transplantation: A single center study

Bedáňová¹,

Orban²,

Třetina³

et al. 2016

BIOMED PAP

View full text Add to dashboard Cite

Aims. The aim of this trial was to use intravascular ultrasound (IVUS) to determine whether cardiac allograft vasculopathy (CAV) starts progressing during the first year after heart transplantation (HTx). Methods. We retrospectively analyzed 51 patients (11 women) who received heart transplants in our center between January 2010 and September 2013 and underwent coronary angiography as well as IVUS examination one month and one year after HTx. Patients with proven calcification and fibrotic plates in the IVUS examination one month after HTx constituted a group with defined donor-transmitted atherosclerosis (DTA). In patients without DTA, measurements of maximal intimal thickening (MIT) were made in two predetermined locations. Results. Eight of the 51 patients had DTA, while 43 did not. These were divided based on maximal intimal thickness (MIT) into a group with MIT < 0.5 mm (27) and MIT ≥ 0.5 mm (16). No patient with MIT < 0.5 mm developed allograft vasculopathy within one year after HTx. CAV developed in three patients (P = 0.045) out of the 16 patients with MIT ≥ 0.5. In patients with DTA, a statistically significant deterioration in percent area stenosis (PAS) occurred in both artery sections (P = 0.01). Conclusion. Our trial showed that CAV progresses during the first year after HTx significantly more frequently in patients with DTA and MIT ≥ 0.5 mm. It is essential in these patients to implement an IVUS control examination one year after transplantation. The results can lead to a change in treatment strategy to prevent further progress of the disease.

show abstract

“…Drug monitoring is done by HPLC coupled with mass spectrometry and an immunoassay is being developed. EvE showed to have antiproliferative effects delaying the onset of cardiac transplant vasculopathy and reducing the rate of CMV infections [77,81]; it is increasingly used, up to 2.6 % in HTx recipients in the years 2008 and 2009 [12]. Due to the favourable effects it may be used in children and is currently investigated (RAD 2313).…”

Section: Everolimusmentioning

confidence: 99%

Immunosuppressive Therapy After Cardiac Transplantation

Schweiger¹

2012

Cardiac Transplantation

View full text Add to dashboard Cite

Effect of Everolimus Introduction on Cardiac Allograft Vasculopathy—Results of a Randomized, Multicenter Trial

Cited by 74 publications

References 23 publications

Detection and Grading of Coronary Allograft Vasculopathy in Children With Contrast-Enhanced Magnetic Resonance Imaging of the Coronary Vessel Wall

Detection and Grading of Coronary Allograft Vasculopathy in Children With Contrast-Enhanced Magnetic Resonance Imaging of the Coronary Vessel Wall

Monitoring of allograft vasculopathy by intravascular ultrasound one month and one year after heart transplantation: A single center study

Immunosuppressive Therapy After Cardiac Transplantation

Contact Info

Product

Resources

About